Piramal Pharma Increases Yapan Bio Stake to 74% for $7.95M, Expands ADC Platform
- Piramal Pharma acquired an additional 40.67% stake in Hyderabad-based CDMO Yapan Bio for ₹76 crore ($7.95 million), raising total ownership to 74%.
- Integration strengthens Piramal's ADCelerate platform for antibody-drug conjugate development and expands large-molecule manufacturing capabilities within Piramal Pharma Solutions.
Operational Impact
Piramal Pharma Solutions now controls Yapan Bio's Hyderabad biologics and vaccine manufacturing footprint as a subsidiary, directly expanding its integrated ADC development capacity from R&D through GMP in under 12 months.
Source: PharmaSource RSS
Andelyn Biosciences to Manufacture AAV9-GM2 Gene Therapy for Queen's University
- Andelyn Biosciences will develop and manufacture AAV9-GM2, a gene therapy for GM2 gangliosidoses (Tay-Sachs and Sandhoff diseases), in partnership with Queen's University.
- Andelyn will deploy its AAV Curator Platform—a modular viral vector manufacturing process with proprietary cell line—to support yield and quality through clinical dosing.
Operational Impact
Andelyn's AAV Curator Platform deployment on the GM2 program demonstrates commercial-stage viral vector manufacturing capability and modular process scalability relevant to CDMO buyers evaluating gene-therapy manufacturing partners.
Source: PharmaSource RSS